Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.48 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214944 | 0.87 | MAPT (0.62) | MAPTLMNAALDH1A1GPR119PDK2 | |
| SCHEMBL30565931 | 0.87 | MAPT (0.62) | MAPTLMNAALDH1A1GPR119PDK2 | |
| SCHEMBL6747471 | 0.85 | PDK2 (0.51) | MAPTLMNAALDH1A1GPR119PDK2 | |
| SCHEMBL31130014 | 0.85 | MAPT (0.56) | MAPTLMNAALDH1A1GPR119PDK2 | |
| SCHEMBL470199 | 0.85 | MAPT (0.56) | MAPTLMNAALDH1A1GPR119PDK2 | |
| SCHEMBL31130013 | 0.85 | MAPT (0.56) | MAPTLMNAALDH1A1GPR119PDK2 | |
| SCHEMBL20352117 | 0.84 | MAPT (0.55) | MAPTLMNAALDH1A1GPR119PDK2 | |
| SCHEMBL7242118 | 0.84 | MAPT (0.56) | MAPTLMNAALDH1A1GPR119PDK2 | |
| SCHEMBL15862951 | 0.82 | LMNA (0.54) | MAPTLMNAALDH1A1GPR119PDK2 | |
| SCHEMBL3613205 | 0.82 | MAPT (0.57) | MAPTLMNAALDH1A1GPR119PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562824-B1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2022-01-26 | — | — | EP | disclosed |
| EP-3562824-B1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
| CN-110167929-A | Oxazole derivatives for treating cancer | 生命弧度公司 | 2019-08-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | PAICS, CDK12, CDK13 | MAPT 4715/4885LMNA 1431/4885ALDH1A1 1713/4885 |
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | PAICS, CDK13, CDK12 | MAPT 4712/4885LMNA 1638/4885ALDH1A1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.